FTSE MIB
33.746,66 -549,65 (-1,60%) Dow Jones
37.928,63 +112,71 (+0,30%) Nasdaq
15.583,09 -74,73 (-0,48%) Nikkei 225
38.274,05 -131,61 (-0,34%) Petrolio
79,42 -2,51 (-3,06%) Bitcoin EUR
53.128,00 -3.693,49 (-6,50%)
Olema Pharmaceuticals, Inc. (OLMA)
| Chiusura precedente | 10,17 |
| Aperto | 10,15 |
| Denaro | 10,33 x 100 |
| Lettera | 10,41 x 100 |
| Min-Max giorno | 9,93 - 10,55 |
| Intervallo di 52 settimane | 5,02 - 17,79 |
| Volume | |
| Media Volume | 793.913 |
| Capitalizzazione | 581,711M |
| Beta (5 anni mensile) | 2,11 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,14 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 24,75 |
GlobeNewswireOlema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor conference call at 8:00 a.m. ET on October 23, 2023 SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced an oral presen
- GlobeNewswire
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced new preclinical data regarding the discovery of novel compounds targeting KAT6, an epig
- GlobeNewswire
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approximately 60 patients Expanded study supports the potential late-stage development of palazestrant in first-line advanced or metastatic breast cancer in combination with ribociclib SAN FRANCISCO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the
